Hematologic side effects of interferon and ribavirin therapy.
about
c-Src protein kinase inhibitors block assembly and maturation of dengue virusFactors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C populationPegylated interferon de novo-induce autoimmune haemolytic anaemia in chronic hepatitis C patient.Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseasesUse of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitisAssociation between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy.KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015.Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan.Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis CPre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients.Toxicity as a result of immunostimulation by biologics.Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis CEarly predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.Hepatitis C comorbidities affecting the course and response to therapyNaturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Risk factors for the development of depression in patients with hepatitis C taking interferon-α.Review: Viral infections and mechanisms of thrombosis and bleeding.Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.Regulation of hematopoietic stem cell activity by inflammation.Current views on interferon therapy for HIV.Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor.Autoimmune hemolytic anemia in HCV/HIV coinfected patients during treatment with pegylated alpha-2a interferon plus ribavirin.Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.Severe autoimmune hemolytic anemia during pegylated interferon plus ribavirin treatment for chronic hepatitis C: a case report.Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.Ribavirin induced anaemia: the effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat.Predictors of changes in hemoglobin levels in patients with chronic hepatitis C treated with ribavirin plus pegylated interferon-α.Discovery of hepatitis C virus NS3 helicase inhibitors by a multiplexed, high-throughput helicase activity assay based on graphene oxide.Efficacy of peg-interferon-α-2a plus ribavirin for patients aged 60 years and older with chronic hepatitis C in Korea.The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection.Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.Treatment Related Hematologic Changes in a Population of Iranian Patients with Chronic Hepatitis C Infection from 2009 to 2014.The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.Pure red cell aplasia caused by ribavirin and interferon treatment.Hepatitis B and hepatitis C viruses: a review of viral genomes, viral induced host immune responses, genotypic distributions and worldwide epidemiology
P2860
Q27478101-9F9504DD-3DAD-4ACF-A2D0-41E65A551F51Q27490831-3A4E049A-D248-479B-B816-AC896018B5ACQ33161405-A20112FB-A699-4567-B2DD-489296EFE2F4Q33284328-D8DA3FD9-DF06-4318-8DC9-736133C94F64Q33394544-ADCFD61B-A027-4D19-83C0-5A72D0B4E30DQ33418008-AA9C1874-FC2A-443B-8142-15439859D073Q33430704-C2FCC19E-74DC-4724-A014-3DE9223254D2Q33908564-9FB43C38-A820-4676-8CC7-9C3A52A08047Q34365412-299E1A78-0BF3-4149-B121-766D6A981243Q35226081-FA08489C-6734-4B85-8164-BCCFDC0D1258Q36059685-34F394C4-D543-477F-882A-DA2D589B9A95Q36699265-17C15E21-B51B-4AE2-9F51-268D6D854997Q36788414-AB1F2E2B-CECB-4563-A016-A5E80E9A0039Q37064110-E7337E1B-2E7B-466C-95FF-C2414221A60FQ37364301-7D5F1FD4-9315-4A1C-8576-BDBBC748E5EAQ37402438-CF50E7E0-7902-48DE-A364-B62DAE924F50Q37426527-95DB89AC-AA00-4204-9D8E-1B341B159634Q37886673-8753C09C-CE31-477A-BAE3-7AC25B383C9EQ38038832-DC24C8BA-BDF7-4C6C-8FE4-22AE3B64224DQ38087506-6FF14FCB-CA08-497F-BA1D-01920A578B99Q38123812-976B6E5C-5AB9-4B84-A9B6-FD15C8D99CCDQ38860634-CEAB7FCC-B27E-474A-BE19-71CDF501B3B2Q39066377-971B6137-B099-4B08-B26A-539A8923800AQ39560823-3D3AD546-BFC1-4C47-B189-96A057A50013Q40707640-56948B37-B049-43B8-A14B-ABA710B9F530Q41497115-013CAF2E-F7E0-440C-B0A7-3E65F68FA6FBQ41600113-03CCDD63-9A4D-41B9-B4D3-E33DEE2072BFQ42205040-673E1FD8-7DD5-4453-BC03-263C3751FCF7Q42965148-4A4AB644-8C33-4A00-8557-A8EA866D24B0Q42977030-7D6850DD-D904-4B26-91FD-2676C3C9456CQ42988665-B64E3DE0-3A76-4E11-BB23-95DA94799B6BQ43034449-B21828E0-9CA3-4D9A-B7BB-31D31C8D32B9Q43036782-066CBA2B-4D2F-424C-8FB1-FBCA84BBB25FQ43041256-EE1B46C1-09DC-4A06-89EE-E81EFAC94895Q45401217-04E56244-0919-492B-AA7A-9D56442EA40BQ45935774-AA2007E8-BAFC-49E5-945B-7F5B7EE02A81Q47199643-52F640D3-5BC1-4C05-97F2-25B96EE51274Q48033815-6697CFB3-52C7-4872-A75B-D7243CF593F5Q50525462-B5D6060F-7A08-490B-B016-1A41DA5D6B06Q56786720-F0833252-A7FA-40CC-AD17-38685C4597C8
P2860
Hematologic side effects of interferon and ribavirin therapy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Hematologic side effects of interferon and ribavirin therapy.
@ast
Hematologic side effects of interferon and ribavirin therapy.
@en
type
label
Hematologic side effects of interferon and ribavirin therapy.
@ast
Hematologic side effects of interferon and ribavirin therapy.
@en
prefLabel
Hematologic side effects of interferon and ribavirin therapy.
@ast
Hematologic side effects of interferon and ribavirin therapy.
@en
P1476
Hematologic side effects of interferon and ribavirin therapy.
@en
P2093
Kris V Kowdley
P356
10.1097/01.MCG.0000145494.76305.11
P433
P577
2005-01-01T00:00:00Z